SIRPα interacts with CD47, a cell surface molecule often over-expressed on cancer cells. The CD47-SIRPα axis limits the antibody-mediated destruction of cancer cells through a ‘don’t eat me ...

which targeted the SIRPα receptor with which CD47 interacts. Last year, AbbVie also pulled out of a $1.3 billion R&D partnership with I-Mab on lemzoparlimab for MDS and AML, for undisclosed ...

Other studies of the CD47-directed antibody in large B cell lymphoma, multiple myeloma and solid tumours are not affected as they don't include azacitidine as a study drug. "While no clear trend ...

CD47 antibodies successfully blocked the binding of CD47 to its ligand signal regulatory protein α (SIRPα). In the BLI affinity assay, the affinity levels of these antibodies were equivalent to ...

Promising pipeline CD47 antigen inhibitors such as IMC-002, MP 0621, HCB-101, PT-217, HX 009, Maplirpacept, IBI 322, ALX-148, HMPL-A83 and others are under different phases of CD47 antigen ...